06-Oct-2022 | Facts and Factors
According to Facts and Factors, the global Peptide Synthesis market size was estimated to be worth roughly USD 509.74 million in 2021 and is predicted to grow to around USD 845.68 million by 2028. The global Peptide Synthesis market is predicted to grow at a CAGR of roughly 7.5% during the forecast period.
When peptides bind to specific cell surface receptors, including ion channels or G protein-coupled receptors (GPCRs), they trigger intracellular events. Peptides are very effective and selective signaling agents. Due to their great pharmacological profile and inherent qualities, peptides are a suitable starting point for the development of novel medicines. Because of their specificity, they are known to have exceptional safety, tolerability, and efficacy qualities in humans. Protein-based biopharmaceuticals are more complex to manufacture than peptide therapies, which results in reduced production costs that are more in line with those of small molecules. The benefits of peptides, such as their availability, low toxicity, and ease of synthesis, led to a growth in their use in the pharmaceutical, food, and cosmetic sectors. This increased demand sped up the development of technology to improve peptide synthesis.
Browse the full “Peptide Synthesis Market Size, Share, Growth Analysis Report By Product (Reagents, Equipment & Services), By Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS) & Hybrid Technology), By Application (Therapeutics, Diagnosis & Research), By End User (Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organization/Contract Research Organization and Academic & Research Institutes), and By Region - Global and Regional Industry Insights, Overview, Comprehensive Analysis, Trends, Statistical Research, Market Intelligence, Historical Data and Forecast 2022 – 2028" report at https://www.fnfresearch.com/peptide-synthesis-market
Peptides are highly effective and specific pharmacological components. Due to the diversity of their biological effects, they are utilized in a wide range of therapeutic applications. Peptides are increasingly being thought of as potential active pharmaceutical ingredients because of their wide chemical space, high biological activity, high specificity, relative simplicity of synthesis, ready availability, and low toxicity. Three significant therapeutic fields that benefit greatly from peptides include oncology, diabetes, and obesity. Peptides are also becoming more important in the management of renal failure, rare disorders, and cardiovascular and neurological diseases. There are already more than 100 drugs based on peptides. With almost 700 peptide medicines and therapeutic peptides now undergoing preclinical research, this figure is anticipated to significantly increase.
The advantages of cutting-edge peptide synthesizers and the increasing research activities and fresh product approvals resulting from increased funding for research and development have further bolstered the growth of the global peptide synthesis market. For instance, ISSAR Pharma declared in April 2021 that it was licensing its peptide-based New Chemical Entities (NCEs), with a pre-investigational new drug (IND) file and the United States patent. Therefore, it is anticipated that such major advancements in peptide medications will increase market demand.
The newest novel coronavirus, COVID-19, is the infectious disease that it causes. Prior to the outbreak's start in Wuhan (China) in December 2019, COVID-19 was largely unknown. It is now a global epidemic. The COVID-19 epidemic has put more strain on the world's healthcare systems. The WHO reports that there were 271,963,258 confirmed COVID-19 cases, with 5,331,019 deaths (as of December 17, 2021). The Americas had the most fatalities, followed by Southeast Asia and Europe.
Important pharmaceutical, biotechnology, and peptide synthesis market participants have increased their R&D spending in response to the COVID-19 epidemic. Peptide synthesis has gained attention due to the increased demand for vaccinations and peptide-based medicines. The peptide-based strategy marks a turning point because peptides have proven to have distinctive characteristics of selectivity and specificity toward particular targets. A peptide-based vaccination candidate called CoVac-1 is made up of SARS-CoV-2 T-cell epitopes derived from several viral proteins, along with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG, with the goal of inducing strong SARS-CoV-2 T-cell immunity to fend off COVID-19. These developments have increased the need for materials and machinery for the manufacture of peptides.
The global Peptide Synthesis market is segmented based on product, technology, application, end use, and region.
Based on product, the market is segmented into reagents, equipment & services. Due to the increasing use of peptides in therapeutics, drug design, and gene synthesis, as well as the frequent purchase of reagents over equipment, the rising number of ongoing research projects involving peptide synthesis, and the availability of various peptide synthesis reagents on the market, the reagents segment is expected to dominate the market share of the global peptide synthesis market during the forecast period.
Based on technology, the market is segmented into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS) & hybrid technology. Due to the fact that the cost of peptide synthesis has significantly decreased as a result of technological advancements and the incorporation of automation in liquid-phase peptide synthesis, the liquid phase peptide synthesis segment is anticipated to dominate the market share of the global peptide synthesis market during the forecast period.
Based on application, the market is segmented into therapeutics, diagnosis & research. Due to the rise in metabolic disorders, such as infectious diseases, pain, dermatological, CNS, renal, and other conditions, the therapeutics segment is predicted to have the lion's share of the worldwide peptide synthesis market during the forecast period.
Based on end use, the market is segmented into pharmaceutical & biotechnology companies, contract development & manufacturing organizations/contract research organizations, and academic & research institutes. Given that peptide treatments are more widely used since they are more affordable, effective, and have lower toxicity, the pharmaceutical & biotechnology firm’s category is predicted to hold the largest market share in 2021.
Due to the rising number of new cancer cases in the region, North America is anticipated to have a dominating position in the global peptide synthesis market. For instance, the American Cancer Association estimates in an article from 2018 that there were around 1,735,350 new cancer cases diagnosed and 609,640 cancer deaths in the United States.
Additionally, the rising accessibility of cutting-edge healthcare infrastructure and significant investments made by the major companies in this region to develop novel peptide synthesis technologies are projected to fuel the market's expansion. For instance, Imcivree (setmelanotide), a pro-opiomelanocortin-derived peptide, was approved by the US Food and Drug Administration (US FDA) in 2020 for chronic weight management (weight loss and weight maintenance for at least one year) in patients aged six and older with obesity brought on by rare genetic conditions. This region's excellent market position in the global market for peptide synthesis is projected to be boosted during the forecast period by the US FDA's drive for expedited drug approval.
Report Scope
Report Attribute |
Details |
Market Size in 2021 |
USD 509.74 Million |
Projected Market Size in 2028 |
USD 845.68 Million |
CAGR Growth Rate |
7.5% CAGR |
Base Year |
2021 |
Forecast Years |
2022-2028 |
Key Market Players |
Bachem Holding AG , Thermo Fisher Scientific , Merck KGaA , GenScript Biotech Corporation , Kaneka Corporation , Biotage AB , Syngene International Ltd. , Mesa Laboratories inc. , CEM Corporation , ProteoGenix , Bio-Synthesis Inc. , Dalton Pharma Services, AAPPTec , Vivitide , AnyGen Co. Ltd. , CSBio , Advanced Chemtech , Luxembourg Bio Technologies Ltd. , JPT Peptide Technologies GmbH , AmbioPharm Inc. , Aurigene Pharmaceutical Services Ltd. , Corden Pharma International , ChemPep Inc. , CPC Scientific Inc. , Purolite Pvt Ltd., and others. |
Key Segment |
By Product, Technology, Application, End User, and Region |
Major Regions Covered |
North America, Europe, Asia Pacific, Latin America, and the Middle East &, Africa |
Purchase Options |
Request customized purchase options to meet your research needs. Explore purchase options |
List of Prominent Players in the Peptide Synthesis Market
- Bachem Holdings (Switzerland)
- Thermo Fisher Scientific (US)
- Merck KGgA (Germany)
- GenScript Biotech Corporation (China)
- Kaneka Corporation (Japan)
- Biotage AG (Sweden)
- Syngen International Ltd (India)
- Mesa Laboratories (US)
- CEM Corporation (US)
- ProteoGenix (France)
- Bio-Synthesis (US)
- Purolite (US)
- ChemPep (US)
- AmbioPharm (US)
- Others
Recent Developments:
In August 2021, Bachem Holding AG (Switzerland) and Novo Nordisk (Denmark) collaborated to develop a greener technology for solid-phase peptide synthesis (SPPS), under which two studies were conducted to find solvent alternatives to replace the reprotoxic N, N-dimethylformamide (DMF), dichloromethane (DCM), and N-methyl-2-pyrrolidone (NMP).
In February 2021, Thermo Fisher Scientific(US) introduced novel capillary chromatography columns for proteomics, clinical peptides, and biopharmaceutical research laboratories performing high throughput, high-performance liquid chromatography (HPLC), or liquid chromatography-mass spectrometry (LC-MS) analysis.
The global Peptide Synthesis market is segmented as follows:
By Product
- Reagents
- Equipment
- Services
By Technology
- Solid Phase Peptide Synthesis (SPPS)
- Liquid Phase Peptide Synthesis (LPPS)
- Hybrid Technology
By Application
- Therapeutics
- Diagnosis
- Research
By End User
- Pharmaceutical & Biotechnology Companies
- Contract Development & Manufacturing Organization/Contract Research Organization
- Academic & Research Institutes
By Region
- North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
About Us:
Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.
Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1 (347) 690-0211
Email: [email protected]
Web: https://www.fnfresearch.com
